From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity
作者:Mohammad Abdel-Halim、Sara Sigler、Nora A. S. Racheed、Amr Hefnawy、Reem K. Fathalla、Mennatallah A. Hammam、Ahmed Maher、Yulia Maxuitenko、Adam B. Keeton、Rolf W. Hartmann、Matthias Engel、Gary A. Piazza、Ashraf H. Abadi
DOI:10.1021/acs.jmedchem.0c01120
日期:2021.4.22
trisubstituted pyrazoline scaffold derived from the COX2 inhibitor, celecoxib, was used to develop novel PDE5 inhibitors. Novel pyrazolines were identified with potent PDE5 inhibitory activity lacking COX2 inhibitory activity. Compound d12 was the most potent with an IC50 of 1 nM, which was three times more potent than sildenafil and more selective with a selectivity index of >10,000-fold against all other PDE
[EN] COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF<br/>[FR] COMPOSITION POUR LE TRAITEMENT DU DIABÈTE ET DE MALADIES MÉTABOLIQUES, ET SON PROCÉDÉ DE PRÉPARATION
申请人:UNIV KAOHSIUNG MEDICAL
公开号:WO2013022951A1
公开(公告)日:2013-02-14
Disclosed is a chalcone composition for treating diabetes and metabolic syndromes. In particular, the chalcone compound bound with 2-halogen in ring A significantly decreases the blood glucose level in the in vitro anti-diabetic effect experiment. In the in vivo animal model, the leading chalcone compound can prevent the progression of diabetes and control the blood glucose level, and there is no significant difference in the gains in body weight. Throughout the seven-week administration, there are no hepatic or renal toxicity observed.
Highly Selective Continuous-Flow Synthesis of Potentially Bioactive Deuterated Chalcone Derivatives
作者:Chi-Ting Hsieh、Sándor B. Ötvös、Yang-Chang Wu、István M. Mándity、Fang-Rong Chang、Ferenc Fülöp
DOI:10.1002/cplu.201402426
日期:2015.5
The selectivesynthesis of various dideuterochalcones as potentiallybioactive deuterium-labeled products is presented, by means of the highly controlled partial deuteration of antidiabetic chalconederivatives. The benefits of continuous-flow processing in combination with on-demand electrolytic D2 gas generation has been exploited to avoid over-reaction to undesired side products and to achieve selective
Isoflavones are synthesized in an one-pot reaction by treating the hypervalent iodine(III) reagent, [hydroxy(tosyloxy)iodo]benzene (HTIB, Koser's reagent) with 2'-benzoyloxychalcones in McOH. A combined use of (diacetoxyiodo)benzene (DIB)/p-toluenesulfonic acid (TsOH) is also effective for the same purpose. As an extension of these monomeric reagents, polymer-supported DIB PSDIB, poly[4-(diacetoxy)iodo]styrene}